Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01431391 · ClinicalTrials.gov registry record · Phase 2
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
A Phase 2 study, sponsored by Dendreon.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT01431391 is a Phase 2 study that has completed, run by Dendreon. The registered enrollment target is 68 participants.
The verdict
NCT01431391, a Phase 2 study, has completed, sponsored by Dendreon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
The main purpose of this study was to determine whether ADT started before or after sipuleucel-T led to a better immune system response. This study also evaluated the safety of sipuleucel-T and ADT treatment, immune system responses over time, the characteristics of sipuleucel-T, and changes in prostate specific antigen (PSA) values over time.
Interventions
- DRUG leuprolide acetate
- BIOLOGICAL sipuleucel-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01431391
The ClinicalTrials.gov registry entry for NCT01431391 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dendreon, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which leuprolide acetate is the first listed.
NCT01431391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01431391 about?
NCT01431391 is a clinical study titled "Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer". The main purpose of this study was to determine whether ADT started before or after sipuleucel-T led to a better immune system response. This study also evaluated the safety of sipuleucel-T and ADT treatment, immune system responses over time, the characteristics of sipuleucel-T, and changes in pros...
What is the current status of trial NCT01431391?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2011-09. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01431391?
The interventions under investigation include: leuprolide acetate (DRUG), sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT01431391?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.